Phase 3 N=10 Triple-Therapy in Patients With HCV Genotype 3 Who Previously Failed Treatment
Hepatitis C
Primary: Sustained Virologic Response (SVR) at 24 Weeks Post Treatment — 6; 3 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=652 Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 1)
Hepatitis C
Primary: Sustained Virological Response 12 Weeks Post-treatment (SVR12) — 79.5; 80.5; 52.3 percentage of participants — p=<0.0001
Phase 3 N=136 Indacaterol EfectIveness In COPD Patients With Tuberculosis History
Patients With Moderate-to-severe COPD With Destroyed Lung by Tuberculosis
Primary: Trough Forced Expiratory Volume in One Second Change — 0.08; -0.06 Liters — p=<0.0001
Phase 3 N=658 Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)
Hepatitis C
Primary: Sustained Virologic Response 12 Weeks Post Treatment (SVR12) — 67.9; 64.3; 47.0 percentage of participants — p=<0.0001
Phase 3 N=269 Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on the Upper Extremities
Actinic Keratosis
Primary: Complete Clearance Rate — 42; 17 participants — p=0.0001
Phase 3 N=246 BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C
Hepatitis C
Primary: Percentage of Participants Achieving Sustained Virologic Response at Post-treatment Week 12 (SVR12) — 50.8; 57.0; 66.7 percentage of participants
Phase 3 N=377 Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Change in HbA1c (Glycosylated Hemoglobin) From Baseline to Week 28 — -1.39; -1.02 Percentage of total hemoglobin — p=0.0072
Phase 3 N=291 Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.
Pulmonary Disease, Chronic Obstructive
Primary: Inspiratory Capacity at Rest Before Constant Work Rate Cycle Ergometry to Symptom Limitation at 75% Work Capacity — 2.502; 2.687; 2.679; 2.776 Litres — p=<0.0001
Phase 3 N=80 Clinical Trial of the Use of Intraperitoneal Local Anaesthetic
Pain, Postoperative
Primary: Reduction in Postoperative Pain — 9.2; 10; 3.3; 9.3 units on a scale
Phase 3 N=120 Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer
Prostate Cancer
Primary: Percentage of Participants Achieving and Maintaining Castrate Levels of Serum Testosterone (<1.735 Nmol/L) — 98.33; 82.61 Percentage of Participants
Phase 3 N=404 A Study to Determine the Effect of Tiotropium + Olodaterol Fixed Dose Combination on Exercise Endurance Time During Constant Work Rate Cycle Ergometry Test in COPD
Pulmonary Disease, Chronic Obstructive
Primary: Adjusted Mean Endurance Time During Constant Work Rate Cycle Ergometry (CWRCE) After 12 Weeks — 463.63; 503.64; 527.51 seconds — p=0.0209
Phase 3 N=295 Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients
Pulmonary Disease, Chronic Obstructive
Primary: Inspiratory Capacity at Rest Before Constant Work Rate Cycle Ergometry to Symptom Limitation at 75% Wcap — 2.440; 2.566; 2.571; 2.658 Litres — p=<0.0001
Phase 3 N=152 Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV
Hepatitis C
Primary: Percentage of Treatment-Naive Participants With Sustained Virologic Response at Follow-up Week 12 (SVR12) Target Detected (TD) or Target Not Detected (TND) — 90.1…
Phase 3 N=279 Studies of the Ocular Complications of AIDS (SOCA)--Cytomegalovirus Retinitis Retreatment Trial (CRRT)
HIV Infections · Acquired Immunodeficiency Syndrome · Cytomegalovirus Retinitis
Primary: Morbidity — 88; 93; 93 participants
Phase 3 N=42 A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome
Short Bowel Syndrome
Primary: Percent Change in Parenteral Support [Parenteral Nutrition (PN)/Intravenous (IV)] Volume at Week 12 — 7.38; -9.95; -37.34; -39.11 percent change